For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Editor's Choice for June 2018

Published: 4 Jul 2018

Views: 2610

Rating:

Save

Prof Gordon McVie - Founding Editor, ecancer

	Journal
	Review: The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy
	Editorial: Propranolol and breast cancer—a work in progress
	Case Report: Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen
	Review: Are aggressive epithelial cancers ‘a disease’ of Eutherian mammals?
	Education
	Breast Cancer CDK 4/6 Inhibitors and Osteonecrosis of the Jaw, multiple languages
	Video
	ASCO 2018 Videos
	EHA 2018 Videos

Related Videos

PARP inhibitors and their evolving role for the treatment of prostate cancer

Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi

PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )

The European Cancer Prevention Organization

Prof. Jaak Janssens - Hasselt, Belgium

The European Cancer Prevention Organization ( Prof. Jaak Janssens - Hasselt, Belgium )

Who does the work in cancer control?

Dr Nazik Hammad - Queen's University, Kingston, Canada

Who does the work in cancer control? ( Dr Nazik Hammad - Queen's University, Kingston, Canada )

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

COVID-19: Management of non-small cell lung cancer patients during the coronavir...

Dr Heather Wakelee - Stanford University, Stanford, USA

COVID-19: Management of non-small cell lung cancer patients during the coronavirus pandemic ( Dr Heather Wakelee - Stanford University, Stanford, USA )

Where have we got to with cancer treatment?

Prof Alexander Eggermont - Princess Máxima Center for Pediatric Oncology, Utrech...

Where have we got to with cancer treatment? ( Prof Alexander Eggermont - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )

How will ASCO combat cancer disparities?

Dr Richard Schilsky and Dr Eduardo Cazap

How will ASCO combat cancer disparities? ( Dr Richard Schilsky and Dr Eduardo Cazap )

The global program of the American Cancer Society

Dr Meg O'Brien - American Cancer Society, Atlanta, USA

The global program of the American Cancer Society ( Dr Meg O'Brien - American Cancer Society, Atlanta, USA )

More from ecancer